Marital Status and Gender Affect Stage, Tumor Grade, Treatment Type and Cancer Specific Mortality in T N M Renal Cell Carcinoma
Overview
Authors
Affiliations
Purpose: To examine the effect of marital status and gender on stage at diagnosis, tumor grade, treatment type and cancer specific mortality (CSM) in patients with localized renal cell carcinoma (RCC).
Methods: Within Surveillance, Epidemiology, and End Results registry (2001-2013), we identified 57,700 patients with T N M RCC. Logistic regression and competing-risks regression models tested the effect of marital status and gender on stage, tumor grade, treatment type and cancer specific mortality (CSM).
Results: Of all patients, 8.8, 10.6 and 14.8% were, respectively, widowed, separated/divorced and never married. The three categories accounted for 3.9, 9.0 and 14.9% of males (35,641) and for 16.7, 13.1 and 14.7% of females (22,059). Widowed (OR 1.13, p = 0.04), separated/divorced (OR 1.16, p = 0.02) and never married status (OR 1.38, p < 0.001) predisposed to higher rate of no surgical treatment. Widowed (HR 1.32, p < 0.001) and separated/divorced (HR 1.32, p < 0.001) status predisposed to higher CSM. Male gender predisposed to higher T-stage (OR 1.12, p < 0.001), higher tumor grade (OR 1.35, p < 0.001), no surgical treatment (OR 1.23, p < 0.001) and higher CSM (1.13, p = 0.01). Interaction tests between gender and marital status failed to reach independent predictor status in all analyses.
Conclusions: Male patients are at higher risk of less favorable baseline characteristics. Additionally, male, widowed and separated/divorced patients exhibit worse cancer control outcomes after treatment for T N M RCC. These observations indicate the need of more focused attention to those patients prior to, as well as after treatment for localized RCC.
Huang X, Tian L, Li C, Liu J, Shi R, Lin F Transl Cancer Res. 2024; 13(11):5898-5908.
PMID: 39697725 PMC: 11651730. DOI: 10.21037/tcr-24-1215.
Xu F, Hua X, Wang M, Cao W, Wang S, Xu C Sci Rep. 2024; 14(1):19079.
PMID: 39154028 PMC: 11330508. DOI: 10.1038/s41598-024-68962-y.
Incorvaia L, Marques Monteiro F, Massari F, Park S, Roviello G, Fiala O Cancer Immunol Immunother. 2024; 73(8):142.
PMID: 38832989 PMC: 11150359. DOI: 10.1007/s00262-024-03719-0.
Bai J, Lu Q, Wen Y, Shangguan T, Ye Y, Lin J Aging (Albany NY). 2024; 16(4):3823-3836.
PMID: 38376430 PMC: 10929802. DOI: 10.18632/aging.205562.
Tang Y, Valovska M, Nolazco J, Yim K, Chung B, Chang S Front Oncol. 2023; 13:1254181.
PMID: 37849800 PMC: 10577411. DOI: 10.3389/fonc.2023.1254181.